SHANGHAI, Dec. 7, 2021 /PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first interim analysis met the primary study endpoint of the overall survival (OS) of the Phase
Loading video.
VIDEO: Cancer treatment is one of the biggest challenges of modern medicine. Research has shown that immune cells can be trained and modified to fight cancer cells. view more
Credit: Cancer Biology & Medicine
Several treatments for cancer have been devised by science, but unfortunately none of them are completely efficient or foolproof. Novel treatments with minimum side effects are one of the main aims of the ongoing cancer research. All research so far points to several therapy modes, of which immunotherapy, which prepares the body s own immune system to fight cancer, is a promising option. Bispecific antibodies (BsAbs) are synthetically made proteins that emerged as a promising second-generation immunotherapy. They engage with immune cells and enable them to target cancer in a specific manner.